Посилання
Ключові статті
National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Повний текст external link opens in a new window
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Повний текст external link opens in a new windowРезюме external link opens in a new window
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Повний текст external link opens in a new windowРезюме external link opens in a new window
Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Повний текст external link opens in a new windowРезюме external link opens in a new window
Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018 May;34(5):506-25.Повний текст external link opens in a new windowРезюме external link opens in a new window
Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Повний текст external link opens in a new windowРезюме external link opens in a new window
Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Повний текст external link opens in a new windowРезюме external link opens in a new window
Перелік літератури
1. National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Повний текст external link opens in a new window
2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Повний текст external link opens in a new windowРезюме external link opens in a new window
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Повний текст external link opens in a new windowРезюме external link opens in a new window
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998 Jun 13;351(9118):1755-62.Резюме external link opens in a new window
5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Повний текст external link opens in a new windowРезюме external link opens in a new window
6. The SPRINT Study Research Group. Systolic Blood Pressure Intervention Trial. 2016 [internet publication].Повний текст external link opens in a new window
7. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Повний текст external link opens in a new windowРезюме external link opens in a new window
8. Geleijinse JM, Kork FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a meta-regression analysis of randomized trials. J Hum Hypertens. 2003 Jul;17(7):471-80.Резюме external link opens in a new window
9. Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000 Oct-Nov;14(10-11):749-63.Повний текст external link opens in a new windowРезюме external link opens in a new window
10. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Dec 4;104(23):2855-64.Повний текст external link opens in a new windowРезюме external link opens in a new window
11. Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr. 2001;10(2):76-80.Резюме external link opens in a new window
12. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1990-2000. A rising tide. Hypertension. 2004 Oct;44(4):398-404.Повний текст external link opens in a new windowРезюме external link opens in a new window
13. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013 Oct;(133):1-8.Повний текст external link opens in a new windowРезюме external link opens in a new window
14. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003 Jul 9;290(2):199-206.Повний текст external link opens in a new windowРезюме external link opens in a new window
15. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322.Повний текст external link opens in a new windowРезюме external link opens in a new window
16. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension. 2002 Feb;39(2):203-8.Повний текст external link opens in a new windowРезюме external link opens in a new window
17. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle aged women and men: the Framingham Heart Study. JAMA. 2002 Feb 27;287(8):1003-10.Повний текст external link opens in a new windowРезюме external link opens in a new window
18. Coggon DI, Martyn CN. Time and chance: the stochastic nature of disease causation. Lancet. 2005 Apr 16-22;365(9468):1434-7.Резюме external link opens in a new window
19. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension. 2004 Jun;43(6):1324-31.Повний текст external link opens in a new windowРезюме external link opens in a new window
20. Andersson OK, Beckman-Suurkula M, Sannerstedt R, et al. Does hyperkinetic circulation constitute a pre-hypertensive state? J Intern Med. 1989 Dec;226(6):401-8.Резюме external link opens in a new window
21. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997 Dec 13;350(9093):1734-7.Резюме external link opens in a new window
22. Weinberger MH. More on the sodium saga. Hypertension. 2004 Nov;44(5):609-11.Повний текст external link opens in a new windowРезюме external link opens in a new window
23. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure: less of one, more the other? Am J Hypertens. 1988 Oct;1(4 Pt 1):335-47.Резюме external link opens in a new window
24. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int. 1996 Jun;49(6):1748-53.Повний текст external link opens in a new windowРезюме external link opens in a new window
25. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996 May 22-29;275(20):1581-9.Резюме external link opens in a new window
26. Laragh JH. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 Jan;14(1):84-9.Резюме external link opens in a new window
27. Fuchs S, Frenzel K, Xiao HD, et al. Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr Hypertens Rep. 2004 Apr;6(2):124-8.Резюме external link opens in a new window
28. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near its solution? Hypertension. 2004 Feb;43(2):154-5.Повний текст external link opens in a new windowРезюме external link opens in a new window
29. Schriffin EL. Remodeling of resistance arteries in essential hypertension and the effects of antihypertensive treatment. Am J Hypertens. 2004 Dec;17(12 Pt 1):1192-200.Повний текст external link opens in a new windowРезюме external link opens in a new window
30. Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy post-menopausal women. J Am Coll Cardiol. 2004 Oct 19;44(8):1636-40.Повний текст external link opens in a new windowРезюме external link opens in a new window
31. Russo C, Oliveri O, Girelli D, et al. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. Hypertension. 1997 Apr;29(4):1058-63.Повний текст external link opens in a new windowРезюме external link opens in a new window
32. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep. 2001 Apr;3(2):152-6.Резюме external link opens in a new window
33. Faxon DP, Creager MA, Smith SC Jr, et al. Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association.. Circulation. 2004 Jun 1;109(21):2595-604.Повний текст external link opens in a new windowРезюме external link opens in a new window
34. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291-7.Повний текст external link opens in a new windowРезюме external link opens in a new window
35. Huang Z, Willet WC, Manson JE, et al. Bodyweight, weight change and risk of hypertension in women. Ann Intern Med. 1998 Jan 15;128(2):81-8.Резюме external link opens in a new window
36. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive patients. Am Heart J. 1993 Apr;125(4):1154-8.Резюме external link opens in a new window
37. Jayedi A, Rashidy-Pour A, Khorshidi M, et al. Body mass index, abdominal adiposity, weight gain and risk of developing hypertension: a systematic review and dose-response meta-analysis of more than 2.3 million participants. Obes Rev. 2018 Jan 15;19(5):654-667.Резюме external link opens in a new window
38. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011 Nov 15;108(10):1499-507.Резюме external link opens in a new window
39. Sarkhosh K, Birch DW, Shi X, et al. The impact of sleeve gastrectomy on hypertension: a systematic review. Obes Surg. 2012 May;22(5):832-7.Резюме external link opens in a new window
40. Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1984 Jul 27;252(4):487-90.Резюме external link opens in a new window
41. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001 Jan 4;344(1):3-10.Повний текст external link opens in a new windowРезюме external link opens in a new window
42. Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med. 2002 Mar 11;162(5):569-74.Повний текст external link opens in a new windowРезюме external link opens in a new window
43. Ding J, Visser M, Kritschevsky SB, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. Am J Hypertens. 2004 Oct;17(10):971-6.Повний текст external link opens in a new windowРезюме external link opens in a new window
44. Bjornholt JV, Erikssen G, Kjeldsen SE, et al. Fasting blood glucose is independently associated with resting and exercising blood pressures and development of elevated blood pressures. J Hypertens. 2003 Jul;21(7):1383-9.Резюме external link opens in a new window
45. Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health. 2018 Jun;8(1):010405.Повний текст external link opens in a new windowРезюме external link opens in a new window
46. United States Department of Agriculture, Center for Nutrition Policy and Promotion. 2015-2020 dietary guidelines for Americans. May 2016 [internet publication].Повний текст external link opens in a new window
47. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937.Повний текст external link opens in a new windowРезюме external link opens in a new window
48. Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens. 2011 Feb;24(2):123-34.Резюме external link opens in a new window
49. US Preventive Services Task Force. High blood pressure in adults: screening. Oct 2015 [internet publication].Повний текст external link opens in a new window
50. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019 Mar 4 [Epub ahead of print].Повний текст external link opens in a new windowРезюме external link opens in a new window
51. Cloutier L, Daskalopoulou SS, Padwal RS, et al. A new algorithm for the diagnosis of hypertension in Canada. Can J Cardiol. 2015 May;31(5):620-30.Повний текст external link opens in a new windowРезюме external link opens in a new window
52. Myers MG. A Short History of Automated Office Blood Pressure - 15 Years to SPRINT. J Clin Hypertens (Greenwich). 2016 Aug;18(8):721-4.Повний текст external link opens in a new windowРезюме external link opens in a new window
53. Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):351-362.Резюме external link opens in a new window
54. Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension. J Hypertens. 2009 Apr;27(4):702-6.Резюме external link opens in a new window
55. Milani RV, Lavie CJ, Mehra MR, et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol. 2006 Apr 1;97(7):959-63.Резюме external link opens in a new window
56. Yasuno S, Ueshima K, Oba K, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens. 2009 Aug;27(8):1705-12.Резюме external link opens in a new window
57. Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009 Sep 22;120(12):1084-90.Резюме external link opens in a new window
58. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916.Резюме external link opens in a new window
59. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018 May;34(5):506-25.Повний текст external link opens in a new windowРезюме external link opens in a new window
60. Dobbin SJH, Cameron AC, Petrie MC, et al. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018 Dec;104(24):1995-2002.Резюме external link opens in a new window
61. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015 Feb 3;162(3):192-204.Повний текст external link opens in a new windowРезюме external link opens in a new window
62. Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev. 2019 Jun 5;6:CD000028.Повний текст external link opens in a new windowРезюме external link opens in a new window
63. Wright Jr JT, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.Повний текст external link opens in a new windowРезюме external link opens in a new window
64. Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430-7.Повний текст external link opens in a new windowРезюме external link opens in a new window
65. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43.Резюме external link opens in a new window
66. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Повний текст external link opens in a new windowРезюме external link opens in a new window
67. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016 May 26;374(21):2009-20.Резюме external link opens in a new window
68. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 May 1;358(18):1887-98.Повний текст external link opens in a new windowРезюме external link opens in a new window
69. Williamson JD, Supiano MA, Applegate WB, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016 Jun 28;315(24):2673-82.Повний текст external link opens in a new windowРезюме external link opens in a new window
70. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA. 2015 Jul 14;314(2):170-80.Резюме external link opens in a new window
71. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Повний текст external link opens in a new windowРезюме external link opens in a new window
72. American Diabetes Association. Standards of medical care in diabetes - 2019. Diabetes Care. 2019 Jan;42(suppl 1):S1-193.Повний текст external link opens in a new window
73. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002 Apr 2;136(7):493-503.Резюме external link opens in a new window
74. Hartley TR, Lovallo WR, Whisett TL, et al. Cardiovascular effects of caffeine in men and women. Am J Cardiol. 2004 Apr 15;93(8):1022-6.Резюме external link opens in a new window
75. Gradman AH, Basile JN, Carter BL, et al; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50.Повний текст external link opens in a new windowРезюме external link opens in a new window
76. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016 Feb 11;352:i438.Повний текст external link opens in a new windowРезюме external link opens in a new window
77. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018 Apr 18;(4):CD001841.Повний текст external link opens in a new windowРезюме external link opens in a new window
78. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97.Повний текст external link opens in a new windowРезюме external link opens in a new window
79. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep;48(3):374-84.Повний текст external link opens in a new windowРезюме external link opens in a new window
80. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003 May;114(7):588-98.Резюме external link opens in a new window
81. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I: mortality results. JAMA. 1982 Mar 26;247(12):1707-14.Резюме external link opens in a new window
82. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992 Sep 3;327(10):669-77.Резюме external link opens in a new window
83. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999 Jul-Aug;5(4):184-5.Резюме external link opens in a new window
84. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8.Повний текст external link opens in a new windowРезюме external link opens in a new window
85. Lindenauer PK, Fitzgerald J, Hoople N, et al. The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade. Arch Intern Med. 2004 Apr 12;164(7):762-6.Повний текст external link opens in a new windowРезюме external link opens in a new window
86. Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Повний текст external link opens in a new windowРезюме external link opens in a new window
87. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 Sep 6;362(9386):782-8.Резюме external link opens in a new window
88. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004 Nov 11;351(20):2058-68.Повний текст external link opens in a new windowРезюме external link opens in a new window
89. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35.Резюме external link opens in a new window
90. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002 Sep 7;360(9335):752-60.Резюме external link opens in a new window
91. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003 Jun;5(3):261-70.Повний текст external link opens in a new windowРезюме external link opens in a new window
92. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens. 2000 May;13(5 Pt 1):468-74.Резюме external link opens in a new window
93. Velasquez EJ, Pfeffer MA, McMurray JV, et al; VALIANT Investigators. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003 Aug;5(4):537-44.Повний текст external link opens in a new windowРезюме external link opens in a new window
94. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.Повний текст external link opens in a new windowРезюме external link opens in a new window
95. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547-52.Резюме external link opens in a new window
96. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049-57.Повний текст external link opens in a new windowРезюме external link opens in a new window
97. Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37.Повний текст external link opens in a new windowРезюме external link opens in a new window
98. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83.Резюме external link opens in a new window
99. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007 Aug 9;120(1):85-91.Резюме external link opens in a new window
100. GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009 Apr 16;360(16):1606-17.Повний текст external link opens in a new windowРезюме external link opens in a new window
101. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.Повний текст external link opens in a new windowРезюме external link opens in a new window
102. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004 Sep;17(9):817-22.Повний текст external link opens in a new windowРезюме external link opens in a new window
103. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized control trial. Lancet. 2004 Sep 4-10;364(9437):849-57.Резюме external link opens in a new window
104. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90.Повний текст external link opens in a new windowРезюме external link opens in a new window
105. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Повний текст external link opens in a new windowРезюме external link opens in a new window
106. Charpentier MM, Bundeff A. Treating hypertension in the very elderly. Ann Pharmacother. 2011 Sep;45(9):1138-43.Резюме external link opens in a new window
107. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung. 2011;61(4):221-8.Резюме external link opens in a new window
108. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013 Aug 21;310(7):699-705.Повний текст external link opens in a new windowРезюме external link opens in a new window
109. Sim JJ, Handler J, Jacobsen SJ, et al. Systematic implementation strategies to improve hypertension: the Kaiser Permanente southern California experience. Can J Cardiol. 2014 May;30(5):544-52.Резюме external link opens in a new window
110. Shaw KM, Handler J, Wall HK, et al. Improving blood pressure control in a large multiethnic California population through changes in health care delivery 2004-2012. Prev Chronic Dis. 2014 Oct 30;11:E191.Повний текст external link opens in a new windowРезюме external link opens in a new window
111. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014 Jul;47(1):86-99.Резюме external link opens in a new window
112. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012 Jan;14(1):51-65.Повний текст external link opens in a new windowРезюме external link opens in a new window
113. Cicolini G, Simonetti V, Comparcini D, et al. Efficacy of a nurse-led email reminder program for cardiovascular prevention risk reduction in hypertensive patients: a randomized controlled trial. Int J Nurs Stud. 2014 Jun;51(6):833-43.Резюме external link opens in a new window
114. McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018 Mar 10;391(10124):949-59.Повний текст external link opens in a new windowРезюме external link opens in a new window
115. Ayanian JZ, Landon BE, Newhouse JP, et al. Racial and ethnic disparities among enrollees in Medicare Advantage plans. N Engl J Med. 2014 Dec 11;371(24):2288-97.Повний текст external link opens in a new windowРезюме external link opens in a new window
116. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003.Резюме external link opens in a new window
117. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ. 2007 May 5;334(7600):946-9.Повний текст external link opens in a new windowРезюме external link opens in a new window
118. Bhatt DL, Kandzari DE, O'Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401.Повний текст external link opens in a new windowРезюме external link opens in a new window
119. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-55.Резюме external link opens in a new window
120. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018 Jun 0;391(10137):2335-45.Резюме external link opens in a new window
121. Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. J Hypertens. 2016 Sep;34(9):1863-71.Повний текст external link opens in a new windowРезюме external link opens in a new window
122. Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2015 Feb;67(2):397-403.Повний текст external link opens in a new windowРезюме external link opens in a new window
123. Fadl Elmula FEM, Feng YM, Jacobs L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension: a systematic meta-analysis. Blood Press. 2017 Aug;26(4):195-203.Повний текст external link opens in a new windowРезюме external link opens in a new window
124. Azizi M, Schmieder RE, Mahfoud F, et al. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019 Mar 17 [Epub ahead of print].Резюме external link opens in a new window
125. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010 Mar;55(3):619-26.Повний текст external link opens in a new windowРезюме external link opens in a new window
126. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006 Dec;44(6):1213-8.Резюме external link opens in a new window
127. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8.Повний текст external link opens in a new windowРезюме external link opens in a new window
128. Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152-158.Резюме external link opens in a new window
129. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011 Dec;162(6):959-65.Резюме external link opens in a new window
130. Juraschek SP, Guallar E, Appel LJ, et al. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012 May;95(5):1079-88.Повний текст external link opens in a new windowРезюме external link opens in a new window
131. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens. 2012 Sep;21(5):492-9.Резюме external link opens in a new window
132. Tamez H, Kalim S, Thadhani RI. Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens. 2013 Mar;22(2):204-9.Повний текст external link opens in a new windowРезюме external link opens in a new window
133. Beveridge LA, Struthers AD, Khan F, et al; D-PRESSURE Collaboration. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015 May;175(5):745-54.Повний текст external link opens in a new windowРезюме external link opens in a new window
134. Cormick G, Ciapponi A, Caffereta ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015 Jun 30;(6):CD010037.Повний текст external link opens in a new windowРезюме external link opens in a new window
135. Tikkanen I, Narko K, Zeller C, et al; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015 Mar;38(3):420-8.Повний текст external link opens in a new windowРезюме external link opens in a new window
136. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.Повний текст external link opens in a new windowРезюме external link opens in a new window
137. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82.Повний текст external link opens in a new windowРезюме external link opens in a new window
138. Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-75.Повний текст external link opens in a new windowРезюме external link opens in a new window
139. Ferdinand KC, Balavoine F, Besse B, et al. Efficacy and safety of firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins. Circulation. 2019 Jul 9;140(2):138-146.Резюме external link opens in a new window
140. Hermida RC, Ayala DE, Mojón A, et al. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012 Mar;25(3):325-34.Резюме external link opens in a new window
141. Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011 Dec;22(12):2313-21.Повний текст external link opens in a new windowРезюме external link opens in a new window
142. Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011 Sep 6;58(11):1165-73.Резюме external link opens in a new window
143. Hermida RC, Ayala DE, Mojón A, et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011 Aug;28(7):601-10.Резюме external link opens in a new window
144. Hermida RC, Ayala DE, Mojón A, et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011 Jun;34(6):1270-6.Повний текст external link opens in a new windowРезюме external link opens in a new window
145. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13.Резюме external link opens in a new window
146. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41.Резюме external link opens in a new window
147. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62.Резюме external link opens in a new window
148. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903.Повний текст external link opens in a new windowРезюме external link opens in a new window
149. Prisant LM, Nalamolu VR. Aortic dissection. J Clin Hypertens (Greenwich). 2005 Jun;7(6):367-71.Повний текст external link opens in a new windowРезюме external link opens in a new window
150. Schmieder RE, Messerli FH. Hypertension and the heart. J Hum Hypertens. 2000 Oct-Nov;14(10-11):597-604.Резюме external link opens in a new window
151. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001 Mar;141(3):334-41.Резюме external link opens in a new window
152. Devereux RB, Roman MJ, Ganau A, et al. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension. 1994 Jun;23(6 Pt 1):802-9.Резюме external link opens in a new window
153. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004 Nov;44(5):595-601.Повний текст external link opens in a new windowРезюме external link opens in a new window
154. Marcantoni C, Ma LJ, Federspiel C, et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002 Jul;62(1):172-80.Повний текст external link opens in a new windowРезюме external link opens in a new window
155. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001 Aug 16;345(7):479-86.Повний текст external link opens in a new windowРезюме external link opens in a new window
156. Poulsen PL, Ebbehoj E, Hansen KW, et al. Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. Am J Hypertens. 1998 Sep;11(9):1093-9.Резюме external link opens in a new window
157. Stamler J, Caggiula AW, Gandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997 Jan;65(1 Suppl):338S-65S.Резюме external link opens in a new window
Використання цього контенту підпадає під нашу відмову від відповідальності